Market participants are focused on obtaining regulatory clearances and increasing the number of collaborations, which is projected to fuel the growth of the worldwide interstitial lung disease market during the forecast period. Throughout the forecast period, the worldwide interstitial lung disease market is likely to be hampered by a lack of knowledge about the condition. Leading market players are focused on obtaining regulatory clearances in order to increase their product portfolio, which is projected to fuel the growth of the worldwide interstitial lung disease market during the forecast period. The growing number of product approvals from regulatory agencies is likely to boost the expansion of the worldwide interstitial lung disease market. An increasing variety of inorganic growth tactics are being developed. The worldwide interstitial lung disease market is predicted to develop due to an increase in the number of inorganic growth methods such as strategic partnership by leading industry participants.
According to Coherent Market Insights, the global Interstitial Lung Disease Market is estimated to be valued at US$ 1,578.9 Mn in 2021 and is expected to exhibit a CAGR of 6.5% over the forecast period (2021-2028).
Prominent Companies in the :
1. MSD (Merck)
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey. News released in February 2023, ACE-1334 by Merck for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) is likelihood of approval
2. Liminal Biosciences
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada. In June 2021, it was released that the company biotech had planned to move into a phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a phase 1b/2a study in hypertriglyceridemia next year.
3. Glenmark Pharma
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, Japan, and internationally. The company was incorporated in 1977 and is based in Mumbai, India. In October 2020, Glenmark Pharma announced the launch of its generic version of Nintedanib (NINDANIB), used for the treatment of pulmonary fibrosis, in India
4. J.B. Chemicals & Pharmaceuticals
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets various pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients in India and internationally. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is based in Mumbai, India. In June 2021, company announced the launch of Nintabid Capsules, an oral anti-fibrotic agent that shows the decline in forced vital capacity associated with Idiopathic Pulmonary Fibrosis.
5. Boehringer Ingelhim International GmbH
Boehringer Ingelheim is a research-driven group of companies dedicated to researching, developing, manufacturing, and marketing pharmaceuticals that improve health and quality of life. Our businesses comprise Prescription Medicine, Animal Health, and Biopharmaceuticals. The company was founded in 1885, headquartered in Germany.
6. F. Hoffmann-La Roche Ltd, Inc.
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally. The company offers pharmaceutical products in the therapeutic areas of oncology, neuroscience, infectious diseases, immunology, hemophilia, ophthalmology, dermatology, respiratory, anemia, inflammatory and autoimmune, and transplantation. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland. On September 2022, Roche to acquire biopharma firm Good Therapeutics for $250m
7. Cipla
Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company was incorporated in 1935 and is headquartered in Mumbai, India.
*Definition- Interstitial lung disease (ILD) is another name for pulmonary fibrosis, which denotes "scarring" and "inflammation" of the interstitium (the tissue that surrounds the lung's air sacs, blood veins, and airways). Scarring stiffens the lung tissue, making breathing harder.
